McDermott Will & Schulte has advised MaaT Pharma, a leading biotech company developing Microbiome Ecosystem TherapiesTM (MET) to improve survival in cancer patients through immune modulation, in the signing of an exclusive long-term license and distribution agreement, with Clinigen, a global pharmaceutical services company specialized in providing ethical access to medicines, for Xervyteg® (MaaT013), the company’s first-in-class therapy for patients with acute Graft-versus-Host Disease (aGvHD).

If approved and granted marketing authorization by mid-2026, the product could become the first microbiome-based therapy approved in Europe, the first in heme-oncology worldwide and the first and only third-line treatment for aGvHD.

The McDermott team included Emmanuelle Trombe, Bertrand Delafaye and Côme de Saint-Vincent, partners and Nejma Palasse, associate.

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.